rsl3

RSL3 (RSL3 1S) is an inhibitor of GPX4, and inhibits system xc- that blocks GSH synthesis (IC50=100 nM). RSL3 is a VDAC-independent activator of ferroptosis that is selective for tumor cells carrying oncogenic RAS.

1R,3R-RSL3 is a negative control for1S, 3R-RSL3.

Demethyl-RSL3 is a PROTAC target protein ligand.

Demethyl-RSL3-boc is a PROTAC target protein ligand.

Liproxstatin-1 is a potent and selective inhibitor of ferroptosis (IC50=22 nM). Liproxstatin-1 protects cells from ferroptosis induced by ferroptosis inducers (e.g., Erastin, RSL3).

trans-3-Indoleacrylic acid is one of the endogenous metabolites that inhibits RSL3-induced ferroptosis and can be used to study colorectal cancer.

iFSP1, a potent, selective, and glutathione-independent ferroptosis suppressor protein 1 (FSP1) (AIFM2) inhibitor with an EC50 of 103 nM, sensitizes diverse human cancer cell lines to ferroptosis inducers like (1S,3R)-RSL3. It uniquely triggers ferroptosis in GPX4-knockout cells overexpressing FSP1.

LOC1886 is a covalent inhibitor of GPX4, with slightly lower potency compared to RSL3 and ML162.

FerroLOXIN-1 is a potent inhibitor of 15LOX-2, selectively blocking the production of ferroptosis-promoting HOO-ETE-PE and preventing RSL3-induced ferroptosis (ferroptosis). It interacts closely and specifically with 15LOX-2, particularly engaging with Y154, N155, and W158.

NYY-6a is a ferroptosis (Ferroptosis) inhibitor, demonstrating significant suppression of RSL3-induced ferroptosis in 786-O and HT-1080 cells, with EC50 values of 52 nM and 50 nM, respectively. As a radical-trapping antioxidant (RTA), NYY-6a effectively reduces lipid peroxidation, comparable to ferrostatin-1 and liproxstatin-1, making it useful for research into ferroptosis-related pathologies.

Ferroptosis-IN-8 (Compound B4) is a potent and specific small molecule inhibitor of ferroptosis, demonstrating a half-maximal inhibitory concentration (IC50) of 40.49 nM. it suppresses RSL3- or FIN56-induced ferroptosis through robust antioxidant mechanisms, alleviates models of hepatorenal injury, and shows significant potential in preventing a spectrum of ferroptosis-related diseases.

15-LOX-1 inhibitor 2 (Compound 5i) is a potent inhibitor of 15-lipoxygenase-1 (15-LOX-1), with an IC50 of 1.7 μM. By inhibiting the activity of the 15-LOX-1 enzyme, it reduces the production of lipid peroxides, thereby preventing lipid peroxidation and protecting cells from RSL3-induced cell death. This compound is valuable for research into cell death mechanisms and oxidative stress-related conditions.

Ferroptosis-IN-13 (compound NY-26) is an inhibitor of ferroptosis. It effectively suppresses RSL3-induced ferroptosis in 786-O cells, with an EC50 value of 62 nM.

FSP1-IN-1 (compound 39) is a potent FSP1 inhibitor with an IC50 of 35 nM. It enhances lipid peroxide accumulation induced by RSL3 and increases cancer cell susceptibility to ferroptosis.

RC363 is an inhibitor of ferroptosis and a derivative of the antioxidant and hypocholesterolemic agent probucol .1It reduces 2,2-diphenyl-1-picrylhydrazyl radicals by approximately 40% in a cell-free assay when used at a concentration of 25 μM. RC363 prevents glutamate-induced toxicity in HT22 cultured hippocampal cells (IC50= 234.5 nM) but does not reduce oxidant levels in these cells. It increases the levels of glutathione peroxidase 1 (GPX1) and the activity of GPX in glutamate-challenged HT22 cells when used at a concentration of 3 μM. RC363 inhibits ferroptosis induced by the GPX4 inhibitor RSL3 in HT22 cells (IC50= 173.6 nM). 1.Bueno, D.C., Canto, R.F.S., de Souza, V., et al.New probucol analogues inhibit ferroptosis, improve mitochondrial parameters, and induce glutathione peroxidase in HT22 cellsMol. Neurobiol.57(8)3273-3290(2020)

RC574 is an inhibitor of ferroptosis and a derivative of the antioxidant and hypocholesterolemic agent probucol .1It inhibits glutamate-induced cell death in HT22 cells (IC50= 276.2 nM) and mouse primary cortical neurons when used at a concentration of 3 μM. RC574 (3 μM) increases glutathione peroxidase 1 (GPX1) levels and GPX activity, as well as inhibits glutamate-induced mitochondrial superoxide anion production, in HT22 cells. It completely inhibits ferroptosis induced by the GPX4 inhibitor RSL3 in HT22 cells when used at concentrations ranging from 62.5 to 1,000 nM. 1.Bueno, D.C., Canto, R.F.S., de Souza, V., et al.New probucol analogues inhibit ferroptosis, improve mitochondrial parameters, and induce glutathione peroxidase in HT22 cellsMol. Neurobiol.57(8)3273-3290(2020)

1-Stearoyl-2-15(S)-HpETE-sn-glycero-3-PE is a phospholipid with stearic acid at the sn-1 position and 15(S)-HpETE at the sn-2 position, produced by oxidation of 1-stearoyl-2-arachidonoyl-sn-glycero-3-PE by 15-lipoxygenase (15-LO). At concentrations of 0.6 and 0.9 μM, it increases ferroptotic cell death in wild-type and Acsl4 knockout Pfa1 mouse embryonic fibroblasts (MEFs) treated with the GPX4 inhibitor RSL3.

NC-R17, an RSL3-based noncovalent GPX4 degrader implicated in ferroptosis, demonstrates anti-tumor activity and is utilized in the design of noncovalent GPX4-targeted proteolysis targeting chimeras (PROTACs) [1].

Ferroptosis-IN-3 (Compound 25), a ferroptosis inhibitor, demonstrates potent activity by inhibiting RSL3-induced ferroptosis in HT-1080 cells (EC50: 8.6 nM). It exhibits radical scavenging abilities against DPPH and ABTS (EC50: 3.94 and 6.3 μM, respectively), and effectively reduces lipid peroxidation [1].

GPX4 24, a derivative of (1S,3R)-RSL3, acts as a potent inhibitor of glutathione peroxidase 4 (GPX4) through covalent binding in a concentration-dependent manner within 4T1 murine mammary carcinoma cells. This compound effectively induces ferroptosis in GPX4-dependent HT-1080 fibrosarcoma cells with an EC50 value of 0.16 µM. Additionally, at a dose of 200 mg/kg, GPX4 24 elevates malondialdehyde (MDA) levels in both kidney and plasma of mice, highlighting its impact on lipid peroxidation.

(R)-HTS-3, a lysophosphatidylcholinacyltransferase 3 (LPCAT3) inhibitor, remodels polyunsaturated phospholipid content in human cells and reduces RSL3-induced ferroptosis in cancer cells.

trans-3-Indoleacrylic acid is one of the endogenous metabolites that inhibits RSL3-induced ferroptosis and can be used to study colorectal cancer.